SCHEMBL7653362

SCHEMBL7653362

COc1nn(-c2ccc(NC(=O)Cc3ccc(Cl)cc3)c(OCc3ccc(F)cc3)c2)c(=O)o1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
MGLL Q99685 1/20 0.49
ABHD16A O95870 1/20 0.48
MAPT P10636 3/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 1/20 0.39
TP53 P04637 1/20 0.39
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7047574 0.90 FAAH (0.49) FAAHMGLLABHD16AMAPTKDM4E
SCHEMBL7044315 0.83 MGLL (0.62) FAAHMGLLABHD16AMAPTALDH1A1
SCHEMBL7046290 0.83 ABHD16A (0.59) FAAHMGLLABHD16AKDM5AKDM5B
SCHEMBL7045850 0.83 MGLL (0.72) FAAHMGLLABHD16ANPC1
SCHEMBL7653357 0.80 ABHD16A (0.48) FAAHMGLLABHD16AKDM5AKDM5B
SCHEMBL7043932 0.78 LPL (0.56) FAAHMGLLABHD16AMAPTKDM4E
SCHEMBL7046310 0.78 ABHD16A (0.61) FAAHMGLLABHD16AKDM5AKDM5B
SCHEMBL7043172 0.75 ABHD16A (0.57) FAAHMGLLABHD16AMAPT
SCHEMBL7040752 0.74 MGLL (0.57) FAAHMGLLKDM4EALDH1A1MEN1
SCHEMBL6600164 0.71 FAAH (0.56) FAAHMGLLMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 FAAH 46/4885MGLL 1542/4885ABHD16A 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.